Special Report: Will the COVID-19 Recovery Be Bumpier than Expected?
Though IVD and commercial lab Q3 2023 earnings reports held promising signs, Q4 2024 and FY2023 results tell a different story.
Keeps You Up-to-Date on Lab Business and Competitive Strategy, Market Trends and Opportunities, and M&A and Investment Activity in Today’s Diagnostic Lab Industry
Though IVD and commercial lab Q3 2023 earnings reports held promising signs, Q4 2024 and FY2023 results tell a different story.
Key approvals announced in June represented important steps forward for the lab testing industry.
The outlook of the global genetic testing market based on recent reports from five financial consulting firms.
After an eventful month in the Illumina-GRAIL saga, the story may soon be over.
The national retailer recently signed a deal with Simple HealthKit to provide Walmart customers online access to at-home diagnostic test kits.
Gather Labs founder and CEO Rachael McCrary discusses how her lab has achieved success beyond COVID-19 testing.
Recent survey provides insight into how current pressures are impacting laboratory staff wages and compensation.
Yet, despite these declines, Q1 was neither as bad as expected nor totally devoid of positive signs for the future.
What should pathology groups and labs do in order to attract and maintain clinical talent in today’s economy?
After a significant lull, M&As in the lab diagnostics space heated up in May, with several key deals announced.
So far, it appears many post-PHE COVID-19 tests will be panels for detecting and differentiating among multiple respiratory viruses.